Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-2

Pralmorelin, Growth Hormone Releasing Peptide-2, KP-102

Quick Stats
Studies 230
Trials 1
Score 3
2000 pubmed

Growth hormone-releasing peptides and the cardiovascular system.

Muccioli. G G; Broglio. F F; Valetto. M R MR; Ghè. C C; Catapano. F F; Graziani. A A; Papotti. M M; Bisi. G G; Deghenghi. R R; Ghigo. E E

Key Findings

  • GHRP receptors are abundant in the heart (ventricles, atria, vessels) and bind the peptide hexarelin strongly.
  • In heart‑derived cell lines, hexarelin (a GHRP) prevents cell death (anti‑apoptotic).
  • Animal and limited human studies show GHRPs protect against ischemic heart damage and increase contractility, independent of GH release.

Practical Outcomes

  • For biohackers interested in cardiovascular health, GHRP‑2 (and related GHRPs) may offer direct heart‑protective benefits beyond GH elevation. However, dosing guidelines are not established, and human data are sparse, so any use should start at the lowest effective dose, be closely monitored, and be combined with standard heart‑health practices.

Summary

Growth hormone‑releasing peptides (like GHRP‑2) don’t just boost GH – they also stick to heart tissue and can protect heart cells, improve heart pumping strength, and reduce damage from low‑oxygen events, even without involving GH.

Abstract

Growth Hormone (GH)-releasing peptides (GHRPs) and their non peptidyl analogues are synthetic molecules which exhibit strong, dosedependent and reproducible GH-releasing activity but also significant PRL- and ACTH/cortisol-releasing effects. An influence of these compounds on food intake and sleep pattern has been also shown. The neuroendocrine activities of GHRPs are mediated by specific receptors subtypes that have been identified in the pituitary gland, hypothalamus and various extra-hypothalamic brain regions with (125)I-Tyr-Ala-hexarelin, an octapeptide of the GHRP family. In addition, GHRP receptors were also present in different peripheral tissues such as heart, adrenal, ovary, testis, lung and skeletal muscle, with a density significantly higher than that found in the hypothalamo-pituitary -system. A remarkable specific (125)I-Tyr-Ala-hexarelin binding was observed in the human cardiovascular system where the highest binding levels were detected in ventricles, followed by atria, aorta, coronaries, carotid, endocardium and vena cava. The binding of the radioligand to cardiac membranes was inhibited by unlabeled Tyr Ala hexare lin and hexarelin as well as by GHRP-6, GHRP-1 and GHRP-2 but not by MK-677, a non peptidyl GHRP analog. In other experiments on H9c2 myocytes, a fetal cardiomyocytes-derived cell line, specific GHRP binding was found and hexarelin showed an anti-apoptotic activity. On the other hand, in vivo studies in animals and in humans showed that GHRPs possess direct cardiotropic actions. In fact, hexarelin protects from ischemia-induced myocardial damage in aged and GH deficient rats while hexarelin shows a positive inotropic effect in normal subjects as well as in patients with GH deficiency. In conclusion, GHRPs possess extra--neuroendocrine biological activity and, particularly, show direct GH-independent cardiotropic effects.

Study Information

Provider

pubmed

Year

2000